Humanwell Healthcare (Group)Ltd Management

Management Kriterienprüfungen 2/4

Humanwell Healthcare (Group)Ltd CEO ist Xiafei Deng , ernannt in Jun 2020, hat eine Amtszeit von 4.42 Jahren. besitzt direkt 0.098% der Aktien des Unternehmens, im Wert von CN¥35.05M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.6 Jahre bzw. 9 Jahre.

Wichtige Informationen

Xiafei Deng

Geschäftsführender

CN¥7.2m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	4.4yrs
Eigentum des Geschäftsführers	0.1%
Durchschnittliche Amtszeit des Managements	4.6yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	9yrs

Jüngste Management Updates

Recent updates

Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump

Oct 21

Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?

Sep 17

There's No Escaping Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Muted Earnings Despite A 26% Share Price Rise

Aug 04

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

May 22

Geschäftsführer

Xiafei Deng (60 yo)

4.4yrs

Amtszeit

CN¥7,185,300

Vergütung

Mr. Xiafei Deng serves as President at Humanwell Healthcare (Group) Co.,Ltd. since June 2020. He serves as Director of Wuhan Humanwell Healthcare (Group) Co.,Ltd.and served as its Vice President until Jun...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xiafei Deng	President & Director	4.4yrs	CN¥7.19m	0.098% CN¥ 35.0m
Yajun Wu	CFO & VP	20.7yrs	CN¥2.08m	0.059% CN¥ 21.3m
Qianlun Li	VP & Secretary	11.5yrs	CN¥1.97m	0.019% CN¥ 6.7m
Wentao Du	Vice President	21.1yrs	CN¥4.07m	0.056% CN¥ 20.0m
Lie Li	Vice President	4.6yrs	CN¥3.70m	0.032% CN¥ 11.4m
Hongjie Zhang	Vice President	no data	CN¥4.97m	0.028% CN¥ 10.0m
Qiang Yin	Vice President	4.6yrs	CN¥1.97m	0.028% CN¥ 10.0m
Qun Yu	Vice President	4.1yrs	CN¥3.69m	0.028% CN¥ 10.0m

4.6yrs

Durchschnittliche Betriebszugehörigkeit

54.5yo

Durchschnittliches Alter

Erfahrenes Management: 600079Das Führungsteam des Unternehmens gilt als erfahren (4.6 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Xiafei Deng	President & Director	25.8yrs	CN¥7.19m	0.098% CN¥ 35.0m
Min Qi	Supervisor	10.5yrs	keine Daten	keine Daten
Rui Zhou	Independent Director	3.5yrs	CN¥100.00k	keine Daten
Lin Qing Liu	Independent director	4.5yrs	CN¥100.00k	keine Daten
Xiao Dong Zhang	Director	27.8yrs	CN¥1.81m	0.029% CN¥ 10.3m
Xuehai Wang	Director	21.5yrs	CN¥618.50k	0.22% CN¥ 80.6m
Jie Li	Chairman of the Board	21.5yrs	CN¥5.67m	5.39% CN¥ 1.9b
Yue Xin Du	Chairman of the Supervisory Board	19.7yrs	CN¥66.00k	keine Daten
Hansheng Zhou	Director	7.6yrs	CN¥1.81m	keine Daten
Chenggang Zheng	Supervisor	4.5yrs	keine Daten	keine Daten
Kong Na	Representative Member of the Supervisory Board	4.5yrs	keine Daten	keine Daten
Xia Yuan	Employee Representative Member of the Supervisory Board	4.5yrs	keine Daten	keine Daten

9.0yrs

Durchschnittliche Betriebszugehörigkeit

55yo

Durchschnittliches Alter

Erfahrener Vorstand: 600079Die Vorstandsmitglieder gelten als erfahren (9 Jahre durchschnittliche Amtszeit).

Humanwell Healthcare (Group)Ltd Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.27 in 3Q 2023)

Investors Still Aren't Entirely Convinced By Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Earnings Despite 42% Price Jump

Upcoming dividend of CN¥0.15 per share

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2024 Results on Oct 30, 2024

Investor sentiment improves as stock rises 21%

Is Humanwell Healthcare (Group)Ltd (SHSE:600079) Using Too Much Debt?

Investor sentiment deteriorates as stock falls 16%

There's No Escaping Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Muted Earnings Despite A 26% Share Price Rise

Second quarter 2024 earnings released: EPS: CN¥0.38 (vs CN¥0.41 in 2Q 2023)

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2024 Results on Aug 15, 2024

Dividend of CN¥0.46 announced

Humanwell Healthcare (Group) Co.,Ltd.'s (SHSE:600079) Low P/E No Reason For Excitement

First quarter 2024 earnings released: EPS: CN¥0.30 (vs CN¥0.41 in 1Q 2023)

Full year 2023 earnings: EPS exceeds analyst expectations

Humanwell Healthcare (Group) Co.,Ltd., Annual General Meeting, Apr 25, 2024

Investor sentiment improves as stock rises 17%

Humanwell Healthcare (Group) Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Second quarter 2023 earnings released: EPS: CN¥0.41 (vs CN¥0.35 in 2Q 2022)

Full year 2022 earnings: EPS in line with analyst expectations despite revenue beat

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.42 (vs CN¥0.27 in 3Q 2021)

Investor sentiment improved over the past week

Second quarter 2022 earnings released: EPS: CN¥0.41 (vs CN¥0.23 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Novo Holdings A/S agreed to acquire The Ritedose Corporation from AGIC Capital, Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) and others.

Third quarter 2021 earnings released: EPS CN¥0.27 (vs CN¥0.16 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.23 (vs CN¥0.19 in 2Q 2020)

Price target decreased to CN¥33.31

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.19 (vs CN¥0.10 in 1Q 2020)

Investor sentiment improved over the past week

New 90-day low: CN¥25.74

Investor sentiment deteriorated over the past week

New 90-day low: CN¥27.26

New 90-day low: CN¥30.20

Humanwell Healthcare (Group) Co.,Ltd. to Report Q3, 2020 Results on Oct 26, 2020

New 90-day low: CN¥30.82

Analysts update estimates

Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) entered into a preliminary letter of intent to acquire an additional 13% stake in YiChang Humanwell Pharmaceutical Co., Ltd from Li Jie, Chen Xiaoqing, and Xu Huabin.

Price target lowered to CN¥10.32

New 90-day high - CN¥38.00

New 90-day high - CN¥36.85

Chongqing Pharmaceutical (Group) Co., Ltd. signed the Sichuan Humanwell Pharmaceutical Co., Ltd. Equity Transfer Contract to acquire 70% stake in Sichuan Humanwell Pharmaceutical Co., Ltd from Humanwell Healthcare (Group) Co.,Ltd. (SHSE:600079) for approximately CNY 360 million.

Humanwell Healthcare (Group) Co.,Ltd. to Report First Half, 2020 Results on Aug 22, 2020

Geschäftsführer

Amtszeit

Vergütung

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter